us-abim MCQ (SBA): CDI-Recurrence Risk

Instant feedback + full explanation. One question, done properly.

ModerateInfectious DiseasesCDI-Recurrence Riskus-abimus-usmle-step-3

A 58-year-old with nonsevere CDI completed fidaxomicin. Which factor supports considering bezlotoxumab to prevent recurrence in a future episode?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

us-abim MCQ: CDI-Recurrence Risk — Answer & Explanation | iatroX